Massimo Imazio, Allan L Klein, Antonio Brucato, Antonio Abbate, Michael Arad, Paul C Cremer, Antonella Insalaco, Martin M LeWinter, Basil S Lewis, David Lin, Sushil A Luis, Stephen J Nicholls, Paul Sutej, Yishay Wasserstrum, JoAnn Clair, Indra Agarwal, Sheldon Wang, John F Paolini
BACKGROUND: Rilonacept, a once-weekly interleukin-1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin-1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Symptomatology and Outcomes Study). The RHAPSODY long-term extension further explored recurrent pericarditis natural history and treatment duration decision-making during 24 additional months of open-label rilonacept treatment. METHODS AND RESULTS: Seventy-four patients commenced the long-term extension, with a median (maximum) total rilonacept duration of 22 (35) months...
March 12, 2024: Journal of the American Heart Association